Gene Therapy Assessments in Clinical Trials

PD 14 – Realizing the Promise of Gene Therapy: Exploring Health System ChallengesПодробнее

Gene Therapy Clinical Trials for Genetic Cardiomyopathies (with Lexeo Therapeutics)Подробнее

Part 1/3 - Navigating the cell and gene therapy supply chain insights, practices and distinctionsПодробнее

Navigating regulatory challenges for cell and gene therapy products in 2024 and beyondПодробнее

(Review) Non-clinical Safety Evaluation for in vivo Gene Therapy ProductsПодробнее

FDA EMA clinical immunogenicity safety assessments first videoПодробнее

FDA EMA clinical immunogenicity safety assessments second videoПодробнее

Health technology assessment (HTA) of genetic therapiesПодробнее

Regulatory considerations in raw material selection for cell and gene therapy manufacturingПодробнее

Assessment and Communication of Risk in Gene Therapy (2024)Подробнее

Gene Therapy Assessments in Clinical Trials (Spanish subtitles)Подробнее

74th Cellular, Tissue, and Gene Therapies Advisory CommitteeПодробнее

Gene Therapy: The Power of Advocacy & Real World Evidence -- PPMD 2023 Annual ConferenceПодробнее

Gene Therapy for Chronic Kidney Disease: A Promising New ApproachПодробнее

76th Cellular, Tissue, and Gene Therapies Advisory CommitteeПодробнее

Webinar: ENVISION Study Update with Sarepta TherapeuticsПодробнее

75th Cellular, Tissue, and Gene Therapies Advisory CommitteeПодробнее

DMD and Gene Therapy What's On the HorizonПодробнее

Cost Savings Related to Qualifying Cell and Gene Therapy FacilitiesПодробнее